ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 487,42
0,51%
Dow Jones
41 696,61
0,18%
DAX
18 726,08
0,52%
Brent Oil
73,345
1,01%
Bitcoin
61 183,00
5,15%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Intellia Therapeutics Inc (NTLA)

  7. Intellia Therapeutics Inc (NTLA) Actualités

NTLA

Intellia Therapeutics (NTLA)

Intellia Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:NTLA
DateHeureSourceTitreSymboleSociété
12/09/202413h30GlobeNewswire Inc.Intellia Therapeutics to Present Data from the Phase 2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the 2024 ACAAI Annual Scientific MeetingNASDAQ:NTLAIntellia Therapeutics Inc
03/09/202422h30GlobeNewswire Inc.Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)NASDAQ:NTLAIntellia Therapeutics Inc
08/08/202422h06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NTLAIntellia Therapeutics Inc
08/08/202413h45Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NTLAIntellia Therapeutics Inc
08/08/202413h30GlobeNewswire Inc.Intellia Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Recent Company ProgressNASDAQ:NTLAIntellia Therapeutics Inc
01/08/202413h30GlobeNewswire Inc.Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2024 Earnings and Company UpdatesNASDAQ:NTLAIntellia Therapeutics Inc
30/07/202413h30GlobeNewswire Inc.Intellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA-3001 for the Treatment of Alpha-1 Antitrypsin DeficiencyNASDAQ:NTLAIntellia Therapeutics Inc
24/07/202422h17Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NTLAIntellia Therapeutics Inc
24/07/202422h13Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:NTLAIntellia Therapeutics Inc
18/07/202422h03Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:NTLAIntellia Therapeutics Inc
02/07/202418h53PR Newswire (US)Kuehn Law Encourages Investors of Intellia Therapeutics, Inc. to Contact Law FirmNASDAQ:NTLAIntellia Therapeutics Inc
26/06/202413h30GlobeNewswire Inc.Intellia Therapeutics Announces CFO TransitionNASDAQ:NTLAIntellia Therapeutics Inc
25/06/202421h30GlobeNewswire Inc.Intellia Announces Positive Clinical Proof-of-Concept Data for Redosing a CRISPR-Based Therapy with its Proprietary LNP-Based Delivery PlatformNASDAQ:NTLAIntellia Therapeutics Inc
17/06/202413h30GlobeNewswire Inc.Intellia Therapeutics to Present the First-Ever Clinical Data From Patients Redosed with an Investigational In Vivo CRISPR Gene Editing Therapy at the Peripheral Nerve Society Annual Meeting 2024NASDAQ:NTLAIntellia Therapeutics Inc
14/06/202413h30GlobeNewswire Inc.Intellia Therapeutics Names Brian Goff to its Board of DirectorsNASDAQ:NTLAIntellia Therapeutics Inc
02/06/202414h00GlobeNewswire Inc.Intellia Therapeutics Announces Positive Long-Term Data from Ongoing Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)NASDAQ:NTLAIntellia Therapeutics Inc
09/05/202413h30GlobeNewswire Inc.Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company ProgressNASDAQ:NTLAIntellia Therapeutics Inc
02/05/202413h30GlobeNewswire Inc.Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2024 Earnings and Company UpdatesNASDAQ:NTLAIntellia Therapeutics Inc
29/04/202413h30GlobeNewswire Inc.Intellia Therapeutics to Present Updated Data from Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Congress 2024NASDAQ:NTLAIntellia Therapeutics Inc
18/03/202412h30GlobeNewswire Inc.Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with CardiomyopathyNASDAQ:NTLAIntellia Therapeutics Inc
26/02/202413h04Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:NTLAIntellia Therapeutics Inc
22/02/202422h02Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:NTLAIntellia Therapeutics Inc
22/02/202413h30GlobeNewswire Inc.Intellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Company ProgressNASDAQ:NTLAIntellia Therapeutics Inc
15/02/202413h30GlobeNewswire Inc.Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic FibrosisNASDAQ:NTLAIntellia Therapeutics Inc
14/02/202413h30GlobeNewswire Inc.Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2023 Earnings and Company UpdatesNASDAQ:NTLAIntellia Therapeutics Inc
31/01/202423h00GlobeNewswire Inc.Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of MedicineNASDAQ:NTLAIntellia Therapeutics Inc
29/01/202422h00Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:NTLAIntellia Therapeutics Inc
08/01/202422h05Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:NTLAIntellia Therapeutics Inc
04/01/202422h01GlobeNewswire Inc.Intellia Therapeutics Highlights its Three-Year Strategic Priorities and Anticipated 2024 Key MilestonesNASDAQ:NTLAIntellia Therapeutics Inc
24/11/202315h30Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:NTLAIntellia Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:NTLA

Dernières Valeurs Consultées

NYSE
NKE
Nike
EU
BN
Danone
EU
AI
Air Liquide
EU
DG
Vinci
EU
RNO
Renault
COIN
DOGEUSD
Dogecoin
EU
VK
Vallourec
EU
CAP
Capgemini
EU
ACA
Credit Agricole
EU
PX4
SBF 120
EU
LR
Legrand
COIN
ADAUSD
Cardano
COIN
SOLUSD
Solana
EU
HO
Thales
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés